NPR-B agonists

Inventors: Frank Osterkamp (Berlin, DE); Heiko Hawlisch (Berlin, DE); Gerd Hummel (Berlin, DE); Tobias Knaute (Berlin, DE); Ulf Reimer (Berlin, DE); Ulrich Reineke (Berlin, DE); Bernadett Simon (Bonn, DE); Uwe Richter (Berlin, DE); Edgar Specker (Berlin, DE); Markus Woischnik (Berlin, DE); Mark R. Helberg (Arlington, TX)

Assignee: Shire Orphan Therapies GmbH

C07K7/06 C07K7/02 C07K7/08

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,196,423
App. No.: 15/975,172
Granted: Feb 5, 2019
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

Claims (35)

1. A compound selected from:

Occ-ala-Nmf-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:111);

Occ-ala-Phe-Aib-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:119);

Occ-ala-Phe-ala-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:120);

Occ-ala-Phe-Ebc-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:121);

Occ-ala-Mcf-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:122);

Occ-Sar-Phe-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:123);

Occ-Gly-Phe-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:124);

Occ-pro-Nmf-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:134);

Occ-Az3-Phe-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:141);

Occ-ala-Thi-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:148);

Occ-ala-Pcf-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:149);

Occ-ala-Thk-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:150);

Occ-ala-Mtf-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:151);

Occ-ala-Mmf-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:152);

Occ-ala-Phe-val-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:155); and

Occ-pip-Phe-Gly-Leu-Pro-Leu-Asp-Arg-Ile-NH 2 (SEQ ID NO:177).

2. The compound of claim 1 , wherein the compound is selected from: